SUBSCRIBE
SUBSCRIBE

Phase I

Drug Development
Biopharma Update on the Novel Coronavirus: September 23
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 23, 2020.
September 22, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: September 21
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 21, 2020.
September 21, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
BioCapital
ESMO News: AstraZeneca, Merck, Janssen, Amgen and More
The European Society for Medical Oncology (ESMO) Virtual Congress 2020 was this weekend, with numerous companies presenting clinical trial data and updates.
September 21, 2020
 · 
4 min read
 · 
Mark Terry
Drug Development
ESMO: Merck and AstraZeneca’s 5-Year Lynparza Data in Ovarian Cancer and More
Biopharma companies focused on oncology continue to release data that will be presented at the 2020 virtual meeting of the European Society of Medical Oncology.
September 18, 2020
 · 
4 min read
 · 
Alex Keown
BioForest
Clinical Catch-Up: September 14-18
It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies.
September 18, 2020
 · 
11 min read
 · 
Mark Terry
Drug Development
Biopharma Update on the Novel Coronavirus: September 18
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 18, 2020.
September 17, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Drug Development
Exicure Announces Positive Phase Ib Trial Results for Solid Tumor Treatment Cavrotolimod
Exicure announced positive results from its Phase Ib trial evaluating cavrotolimod, its SNA-enabled TLR9 agonist, that is being developed for the treatment of solid tumors, in combination with pembrolizumab.
September 17, 2020
 · 
3 min read
 · 
Krystle Vermes
Policy
Biopharma Update on the Novel Coronavirus: September 16
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 16, 2020.
September 16, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: September 14
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 14, 2020.
September 14, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
BioCapital
Clinical Catch-Up: September 7-11
It was a busy week for clinical trial updates. Here’s a look.
September 11, 2020
 · 
10 min read
 · 
Mark Terry
Load More
PRESS RELEASES
Drug Development
NeuShen Therapeutics Initiates First-in-Human Trial of NS-136, a Novel Selective M4 Receptor Positive Allosteric Modulator for the Treatment of Schizophrenia
May 8, 2024
 · 
2 min read
Drug Development
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
May 8, 2024
 · 
4 min read
Drug Development
Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586
May 8, 2024
 · 
7 min read
Drug Development
Acepodia Announces Preliminary Clinical Data From Phase 1 Clinical Trial of ACE1831, First-Ever Anti-CD20 Antibody Conjugated Allogenic Gamma Delta T Cell Therapy for Non-Hodgkins Lymphoma
May 8, 2024
 · 
4 min read
Drug Development
Minghui Pharmaceutical to Present the Phase I/II Study of MHB088C (B7-H3 ADC) for the Treatment of Patients with Recurrent or Metastatic Solid Tumors in Late-breaking Oral Presentation at the 2024 ASCO Annual Meeting
May 8, 2024
 · 
3 min read
Drug Development
FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia
May 7, 2024
 · 
7 min read
Drug Development
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
May 7, 2024
 · 
5 min read
Drug Development
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting
May 7, 2024
 · 
8 min read
Drug Development
EyeDNA Therapeutics Announces Positive 24-month Data Presented at ARVO from Ongoing Phase I/II Trial of HORA-PDE6b Gene Therapy in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b
May 7, 2024
 · 
6 min read
Drug Development
Adcentrx Therapeutics Announces China NMPA Grants IND Clearance for ADRX-0706, a Novel Nectin-4 ADC for the Treatment of Advanced Solid Tumors
May 6, 2024
 · 
3 min read
Drug Development
OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
May 6, 2024
 · 
11 min read
Drug Development
Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
May 6, 2024
 · 
5 min read
Drug Development
Mediar Advances First-in-Class Fibrosis Portfolio to the Clinic with First Cohort Dosing in Phase 1 trial of MTX-463 and Establishes Clinical Advisory Board
May 6, 2024
 · 
4 min read
Drug Development
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
May 6, 2024
 · 
4 min read
Drug Development
Ventus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively to Novo Nordisk
May 3, 2024
 · 
6 min read
Drug Development
Guangzhou Bio-gene Technologies Announces Initiation of Phase I Clinical Trial for BG1805, a CAR-T Targeting CLL-1
May 2, 2024
 · 
2 min read
Drug Development
Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76
May 2, 2024
 · 
4 min read
Drug Development
Alpha-9 Oncology Announces First Patient Dosed in Phase 1 Study of A9-3202 in Patients with Locally Advanced or Metastatic Melanoma
May 2, 2024
 · 
2 min read
Drug Development
Remix Therapeutics Announces First Patients Dosed in Two Phase 1 Clinical Trials Investigating REM-422 for Treatment of Adenoid Cystic Carcinoma (ACC) and Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS)
May 2, 2024
 · 
4 min read
Drug Development
Smart Immune treats adult acute leukemia patient at final dose level in Phase I/II ReSET-02 trial
May 2, 2024
 · 
3 min read
Load More